Navigation Links
Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
Date:3/20/2008

our clinical program for NPI-2358 and involve first-rate cancer research centers with unique expertise with this class of vascular disrupting agents," said Kobi M. Sethna, President and CEO, Nereus Pharmaceuticals, Inc.

Upon successful completion of the Phase 1b trial and determination of the recommended doses for the combined agents, Nereus expects to advance NPI-2358 into an international randomized Phase 2 study of approximately 150 patients at 30 centers late in 2008. Nereus is also evaluating NPI-2358 in other solid tumor indications.

About NPI-2358 -- A Novel Vascular Disrupting Agent

NPI-2358 is a vascular disrupting agent currently in clinical development for the treatment of cancer by Nereus. Initial results from a single-agent Phase 1 trial in various tumor types indicate NPI-2358 has a favorable safety profile, including cardiac safety. It is also being evaluated in a Phase 1b study in combination with docetaxel for the treatment of non-small cell lung cancer. NPI-2358 is one of over 200 synthetic analogues that were prepared following the discovery of the compound Halimide isolated from a marine fungus. In preclinical models of cancer, including lung, breast, sarcoma, colon and prostate, NPI-2358 demonstrated potent and selective anti-tumor effects in combination with docetaxel and other oncology therapies, as well as single-agent efficacy in a number of orthotopic models. NPI-2358 interacts with soluble beta-tubulin and prevents the polymerization of tubulin without altering dynamic microtubule function of formed microtubules. As demonstrated in preclinical testing, this target profile results in a highly specific nanomolar cytotoxicity while reducing the side effects seen in first-generation VDAs due to cardiotoxicity, hemodynamic changes and neuropathies.

About Nereus Pharmaceuticals, Inc.

Nereus Pharmaceuticals pursues novel sources of chemical diversity to discover and develop new therapeutics. Using its unmatched
'/>"/>

SOURCE Nereus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --  ISN has released its third annual U.S. ... publication series. With data aggregated from over eight billion ... its online contractor management platform, ISNetworld, this three-part series ... statistics. The Contractor Performance ... available in two industry specific volumes: Oil & ...
(Date:12/17/2014)... 17, 2014 Achim Noack has been ... Stoller Group. In this position, Noack will assist Jerry ... matters, develop marketing strategy and supervise global marketing management ... “Achim has tremendous knowledge and experience in the crop ... “His experience and innovative thinking will be a great ...
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... BETHESDA, Md., Sept. 16 Micromet, Inc. (Nasdaq: MITI ), ... inflammation and autoimmune diseases, today announced that its President and CEO, Dr. ... September 22, 2009 in New York City. A simultaneous webcast of ... , , ...
... ... RPCI is to develop, optimize, and perform high-throughput insertional mutagenesis screens to identify potential ... ... research company which performs high-throughput (HT) RNAi and peptide genetic screens for novel therapeutic ...
... , , CINCINNATI, Sept. 16 ... research organization, today announced the Company will participate in the upcoming ... Grand Hyatt New York Hotel in New York City. , ... , , Kendle,s formal presentation will be given ...
Cached Biology Technology:Micromet to Present at the UBS Global Life Sciences Conference on September 22, 2009 2Micromet to Present at the UBS Global Life Sciences Conference on September 22, 2009 3CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc. 2CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc. 3Kendle to Present at UBS Global Life Sciences Conference 2
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... A new study that provides a snapshot of a ... of physical activity are strongly associated with being overweight or ... in fruits and vegetables did little to offset the effect ... who were mostly sedentary. Instead, exercise seemed to be the ...
... March 24 An experimental vaccine against an abnormal protein ... onset of inflammatory bowel disease (IBD) and in turn prevent ... of Pittsburgh School of Medicine. Their findings are reported this ... the American Association for Cancer Research. People with chronic ...
... A Worcester Polytechnic Institute (WPI) research team has ... Institutes of Health (NIH) to continue a groundbreaking study ... that will enable physicians to predict the likelihood of ... and strokes. Led by Dalin Tang, PhD, professor of ...
Cached Biology News:Rochester study connects workplace turmoil, stress and obesity 2Rochester study connects workplace turmoil, stress and obesity 3Rochester study connects workplace turmoil, stress and obesity 4Vaccine could delay bowel inflammation and colon cancer, says Pitt research 2WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease 2WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease 3
...
...
... PCR Cloning Kit offers the fastest ... cloning of blunt-end PCR products amplified ... includes the linearized and topoisomerase I-activated ... ligations without ligase (1). The pCR-Blunt ...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Biology Products: